Cel Since 2010, AXENIS has developed proprietary, state-of-the-art humanized mouse models as preclinical tools for biomedical research and biopharmaceutical industry in the field of immunology, infectious diseases, immuno-oncology and inflammation. Humanised mice are extremely attractive and effective to perform a fine evaluation of new therapeutic and diagnostic options in a human-like environment. Overall, humanized mouse preclinical testing benefit to the patients (safer products) and pharmaceutical companies (upfront pre-clinical screening of molecules reducing clinical development costs).To become a global European leader addressing the health market needs for humanized mouse models, the humanized mouse production activity of the company requires to be scaled up to an industrial level that will better suit the end-users’ expectations. That is a reason why a feasibility study is needed to help AXENIS accessing a comprehensive survey of production scale-up (at least 10-fold) from current ‘low scale level’ (few hundred units per year) to the level of multiple of thousand units per year under optimal regulatory standards; an evaluation of the production costs with the aim of lowering the unit price by at least two; precise valuation of the demand market segments; and a risk assessment of the scale-up project. The HUMANMICE project is therefore the basis to the future development of the company, to establish humanized mice as a new standard for preclinical studies, develop the next generation of humanized mouse models, create an environment supporting business & collaboration opportunities, minimize the production costs and maximize the corresponding revenues. Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesbasic medicineimmunologymedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Program(-y) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Temat(-y) BIOTEC-5a-2014-1 - SME boosting biotechnology-based industrial processes driving competitiveness and sustainability Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2014 System finansowania SME-1 - SME instrument phase 1 Koordynator AXENIS Wkład UE netto € 50 000,00 Adres PASTEUR BIOTOP 28 RUE DU DOCTEUR ROUX 75015 PARIS Francja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Ile-de-France Ile-de-France Paris Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
